公司资料
Freeline Therapeutics 股价、新闻与催化剂
- 股票代码:
- FRLN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United Kingdom and traded in the U
股价为何变动
Current closing-price context is not available for FRLN.
公司概览
业务概览
Freeline Therapeutics was a gene-therapy company focused on treating serious diseases through AAV-based gene delivery. Its story centered on whether a gene-therapy platform could create durable value in rare disease.
所在地与行业分类
Freeline was headquartered in the United Kingdom and traded in the U.S. market. It sat in gene therapy and rare-disease biotechnology.
商业模式特征
The company depended on clinical proof, manufacturing readiness, and capital efficiency in a tough gene-therapy environment. Investors watched data, safety, and strategic optionality.
生物医药行业定位
Freeline occupies a historical gene-therapy niche within biotech. It was highly sensitive to platform validation because the market needed evidence that the approach could scale.
未来催化剂
- Freeline is now a legacy / closeout story, with catalysts limited to any residual transaction or asset-resolution update. There is no active standalone pipeline story left.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。